RE:RE:RE:RE:RE:Jan 31, 2018 Financials MD&AAgree - the TSX review is a non-issue. The most important tidbit I got from the MDA is ... "As announced on August 28, 2017, we received a letter of intent regarding a significant potential regional licensing arrangement and/or a significant equity investment in Resverlogix." Perhaps the LOI is is on hold until the futility analysis is in (or whatever they are calling it these days); or Don is pushing off finalization until then to maximize the value to be obtained (or minimize dilution). The MDA also states that management is confident in obtaining financing to cover future costs ($500k in cash and almost $16 million in payables as of 1/31 - so it seems their study vendors are, as well). too bad we can't get cash now - so they can start the renal work.